Trial · NCT05843786
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
NCT05843786, Phase 3, Recruiting, Hospices Civils de Lyon
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients. Trials, record NCT05843786. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05843786
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
- NCT number
- NCT05843786
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 132 participants, estimated
- Lead sponsor
- Hospices Civils de Lyon
- Conditions
- Pneumonia, Ventilator-Associated
- Interventions
- Interferon gamma, Placebo
- First posted
- 2023-05-06
- Last updated
- 2026-07-06
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | duration of mechanical ventilation assessed from the first day of VAP diagnosis | Day 28 | mechanical ventilation-free days (VFD) from extubation through D28. A beneficial effect of using recombinant human interferon gamma-1b would be a statistically significant increase in VFD in patients receiving study drug in this setting compared to the group receiving placebo. |
| Secondary | All-cause mortality in intensive care | Day 28 | |
| Secondary | Previous positive microbiological sample at inclusion becomes negative | Day 5 | Previous positive microbiological sample at inclusion becomes negative, i.e. pulmonary, urinary, blood cultures |
| Secondary | Length of stay in intensive care unit | Day 28 | |
| Secondary | length of stay at hospital | Day 28 | |
| Secondary | occurrence of another episode of VAP before extubation | Day 28 | |
| Secondary | occurrence of another episode of infection acquired in intensive care unit | Day 28 | |
| Secondary | increase of monocytic HLA-DR expression above 8000 AB/C the day after the last dose of treatment (J5) | Day 28 | |
| Secondary | increase or decrease of blood leucocyte count at the day after the last dose of treatment (J5) in comparison to baseline | Day 28 | |
| Secondary | Evaluation of the economic efficiency of the administration of IFN-γ (assessed by the ACER (average cost-effectiveness ratio) method) | Day 28 | Evaluation of the cost-effectiveness of IFN-γ administration (assessed by the ACER (average cost-effectiveness ratio) method) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05843786
GET https://conductscience.org/api/trials/v1/NCT05843786/registered